Skip to main content

Advertisement

Table 1 Characteristics of patients enrolled in the study

From: A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma

No Age/gender Child-Pugh (Score) Size and number of tumors KPS (%) PBT dose/frac Dose of Cal-TUMP
Location (Size) Number (LN)
1 73/M A (5) S4/5/8 (110 mm), S5/6 (8 mm), Lymph node (10 mm) 3 (1) 90 74 GyE/37f 1/10
2 55/M A (6) S3 (34 mm), S4 (58 mm, 8 mm), S8 (10 mm) 4 (0) 90 72 GyE/37f 1/10
3 52/M A (5) right lobe (110 mm), S3 (44 mm, 70 mm) 3 (0) 90 72.6 GyE/22f 1/10
4 63/M A (5) S1 (26 mm, 18 mm), portal region (19 mm) 3 (0) 90 72.6 GyE/22f 1/3
5 65/M B (8) S4 (87 mm), S5/7/8 (10 mm × 4) 5 (0) 90 52.8 GyE/16f 1/3
6 65/M A (5) S5 (54 mm), S1 (27 mm), S4 (8 mm) lateral segment of left lobe (12 mm), Lymph node (12 mm) 5 (1) 90 87.6 GyE/27f 1/3
7 59/M A (6) S5/8 (20 mm) 1 (0) 100 72.6 GyE/22f 1/1
8 72/M A (5) In the vicinity of IVC (46 mm) 1 (0) 90 72.6 GyE/22f 1/1
9 71/F A (5) S8 (14 mm, 14 mm) 2 (0) 100 72.6 GyE/22f 1/1
  1. (LN: Lymph node, KPS: Karnofsky performance status, PBT: Proton beam radiotherapy, Dose.frac: Total dose/fraction number).